Adam is a serial entrepreneur and regenerative medicine executive with deep expertise in business development and company building. He helped scale the first commercial exosome company and several autologous technologies to $50M in global sales in under three years. Previously, he launched a neuromodulation startup that competed directly with Medtronic, Boston Scientific, and Abbott. Adam is skilled at forming high-performance teams and aligning inventors to advance emerging technologies across quantum computing, computational biology, and nanotechnology.

Dmitry Green combines deep scientific and financial expertise, building investments in quantum technologies. He has held leadership positions in hedge funds for over 15 years and conducted a research program as an Adjunct Professor of Physics at Boston University, contributing to topological quantum computing. He is currently focused on developing topological quantum computers and advises hedge funds on portfolios, strategies, and risk management.